苯妥英钠代谢受磺胺噻唑抑制的癫痫患者。
Inhibition of phenytoin metabolism by sulthiame in epileptic patients.
机构信息
Department of Clinical Pharmacology, St Bartholomew's Hospital, London.
出版信息
Br J Clin Pharmacol. 1974 Feb;1(1):59-66. doi: 10.1111/j.1365-2125.1974.tb00207.x.
Abstract
1 Measurements have been made of steady state serum phenytoin concentration, serum half-life of (14)C-labelled phenytoin, and the urinary ratio of the major metabolite of phenytoin to the unchanged drug (p-HPPH: DPH ratio) in epileptic patients on and off sulthiame therapy. 2 Starting sulthiame treatment produced an increase in serum phenytoin concentration, a prolongation of the half-life and an increase in the p-HPPH: DPH ratio. The total urinary output of phenytoin plus p-HPPH was unaltered by sulthiame. 3 The results indicate that sulthiame or one of its metabolites inhibits the parahydroxylation of phenytoin by hepatic enzymes.
摘要
我们对正在使用和停用氨苯砜治疗的癫痫患者的稳态血清苯妥英浓度、（14）C 标记的苯妥英的血清半衰期以及苯妥英的主要代谢物与未改变的药物的尿比值（p-HPPH:DPH 比值）进行了测量。
氨苯砜治疗开始后，血清苯妥英浓度增加，半衰期延长，p-HPPH:DPH 比值增加。氨苯砜治疗并未改变苯妥英加 p-HPPH 的总尿排出量。
结果表明，氨苯砜或其代谢物之一抑制了肝酶对苯妥英的对羟化作用。
相似文献
1
Inhibition of phenytoin metabolism by sulthiame in epileptic patients.
Br J Clin Pharmacol. 1974 Feb;1(1):59-66. doi: 10.1111/j.1365-2125.1974.tb00207.x.
2
Rate of elimination of tracer doses of phenytoin at different steady-state serum phenytoin concentrations in epileptic patients.
Br J Clin Pharmacol. 1974 Apr;1(2):155-61. doi: 10.1111/j.1365-2125.1974.tb00225.x.
3
Michaelis-Menten kinetics and the steady-state serum phenytoin/hydroxyphenytoin ratio.
Ther Drug Monit. 1985;7(4):405-10. doi: 10.1097/00007691-198512000-00007.
4
Phenytoin metabolism in subjects with long and short plasma half-lives.
Ther Drug Monit. 1982;4(3):281-92. doi: 10.1097/00007691-198208000-00006.
5
Phenytoin metabolism in mice.
Drug Metab Dispos. 1982 Mar-Apr;10(2):156-60.
6
Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.
J Pharmacol Exp Ther. 1987 May;241(2):615-22.
7
Comparative drug elimination in man-diphenylhydantoin and amobarbital.
Eur J Clin Pharmacol. 1975 Oct 10;9(1):79-83. doi: 10.1007/BF00613433.
8
Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth.
J Periodontal Res. 1999 Apr;34(3):145-53. doi: 10.1111/j.1600-0765.1999.tb02235.x.
9
Studies by biointeraction chromatography of binding by phenytoin metabolites to human serum albumin.
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 19;836(1-2):83-91. doi: 10.1016/j.jchromb.2006.03.043. Epub 2006 Apr 18.
10
Metabolism of diphenylhydantoin (phenytoin) during pregnancy.
Br J Obstet Gynaecol. 1979 Feb;86(2):125-32. doi: 10.1111/j.1471-0528.1979.tb10579.x.
引用本文的文献
1
Sulthiame monotherapy for epilepsy.
Cochrane Database Syst Rev. 2021 Sep 23;9(9):CD010062. doi: 10.1002/14651858.CD010062.pub3.
2
Sulthiame monotherapy for epilepsy.
Cochrane Database Syst Rev. 2014 Mar 9;2014(3):CD010062. doi: 10.1002/14651858.CD010062.pub2.
3
Pharmacokinetic interactions with antiepileptic drugs.
Clin Pharmacokinet. 1982 Jan-Feb;7(1):57-84. doi: 10.2165/00003088-198207010-00004.
4
Drug interactions with phenytoin.
Drugs. 1981 Feb;21(2):120-37. doi: 10.2165/00003495-198121020-00003.
5
The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation.
Clin Pharmacokinet. 1987 Apr;12(4):253-91. doi: 10.2165/00003088-198712040-00002.
6
Drug interactions that matter. A critical reappraisal.
Drugs. 1988 Jul;36(1):83-110. doi: 10.2165/00003495-198836010-00006.
7
Antiepileptic drug toxicity: definition and mechanism of action.
Ital J Neurol Sci. 1986 Apr;7(2):209-22. doi: 10.1007/BF02230884.
8
Pharmacokinetic drug interactions with phenytoin (Part II).
Clin Pharmacokinet. 1990 Feb;18(2):131-50. doi: 10.2165/00003088-199018020-00004.
9
Drug interactions and clinical pharmacokinetics.
Clin Pharmacokinet. 1976;1(5):351-72. doi: 10.2165/00003088-197601050-00003.
10
Clinical pharmacokinetics of phenytoin.
Clin Pharmacokinet. 1979 May-Jun;4(3):153-69. doi: 10.2165/00003088-197904030-00001.
本文引用的文献
1
THE USE OF OSPOLOT IN THE TREATMENT OF EPILEPSY.
Epilepsia. 1964 Mar;5:68-73. doi: 10.1111/j.1528-1157.1964.tb04347.x.
2
Clinical trial of Ospolot in epilepsy.
Dev Med Child Neurol. 1963 Jun;5:313-5.
3
Some causes of ineffectiveness of diphenylhydantoin.
Arch Neurol. 1966 May;14(5):489-92. doi: 10.1001/archneur.1966.00470110033004.
4
The rate of decline of diphenylhydantoin in human plasma.
Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121-34. doi: 10.1002/cpt1970111121.
5
Effect of dosage increments on blood phenytoin concentrations.
J Neurol Neurosurg Psychiatry. 1972 Dec;35(6):873-6. doi: 10.1136/jnnp.35.6.873.
6
Drug--interaction between sulthiame (Ospolot (R)) and phenytoin in the treatment of epilepsy.
Dan Med Bull. 1969 May;16(5):154-8.
7
Sulthiame (Ospolot) as inhibitor of diphenylhydatoin metabolism.
Epilepsia. 1968 Mar;9(1):17-22. doi: 10.1111/j.1528-1157.1968.tb04954.x.
8
Pharmacokinetic study of a patient with diphenylhydantoin toxicity.
Clin Pharmacol Ther. 1973 Jul-Aug;14(4):521-8. doi: 10.1002/cpt1973144part1521.
9
Proceedings: Inhibition of phenytoin metabolism by sulthiame.
Br J Pharmacol. 1973 Sep;49(1):157P-158P.
Zotero 插件